Parties d'ouvrages collectifs (2)
  1. 1. Ando, K., Laborde, Q., Brion, J. P., & Duyckaerts, C. (2018). 3-D imaging in post-mortem human brain with CLARITY and CUBIC. In I. Huitinga & M. Webster (Eds.), 3D imaging in the postmortem human brain with CLARITY and CUBIC, Vol. 150. Brain Banking in Neurologic and Psychiatric Diseases (pp. 303-317). Elsevier.(Handbook of Clinical Neurology). doi:10.1016/b978-0-444-63639-3.00021-9
  2. 2. Ando, K. (2014). Alzheimer risk factor, PICALM is involved in tau pathology in Alzheimer and other tauopathies. In Psychiatry Today (p. 15). Tokyo, Japan: Haruyoshi Kato.
    3.   Articles dans des revues avec comité de lecture (47)
  3. 1. Ando, K., Kosa, A.-C., Mehadji, Y., Lasri, H., López Gutiérrez, L., Quintanilla Sanchez, C., Aydin, E., Doeraene, E., Wathelet-Depauw, A., Nagaraj, S., Brion, J. P., & Leroy, K. (2025). Deletion of Murine APP Aggravates Tau and Amyloid Pathologies in the 5xFADXTg30 Alzheimer’s Disease Model. Biomolecules, 15(2), doi.org/10.3390/biom15020159, 159.
  4. 2. Nagaraj, S., Quintanilla Sanchez, C., Ando, K., López Gutiérrez, L., Doeraene, E., Kosa, A.-C., Aydin, E., Brion, J. P., & Leroy, K. (2024). Downregulation of hsa-miR-132 and has-miR129: non-coding RNA molecular signatures of Alzheimer's disease. Frontiers in Molecular Neuroscience, 17(2), 10.3389/fnmol.2024.1423340.
  5. 3. Ando, K., Küçükali, F., Doeraene, E., Nagaraj, S., Antonelli, E. M., Htut Thazin, M., Yilmaz, Z., Kosa, A.-C., López Gutiérrez, L., Quintanilla Sanchez, C., Aydin, E., Ramos, A. R., Mansour, S., Turbant, S., Schurmans, S., Sleegers, K., Erneux, C., Brion, J. P., & Leroy, K. (2024). Alteration of gene expression and protein solubility of the PI5- phosphatase SHIP2 are correlated with Alzheimer's disease pathology progression. Acta Neuropathologica, 147(94), 10.1007/s00401-024-02745-7.
  6. 4. Ando, K., Nagaraj, S., Küçükali, F., De Fisenne, M.-A., Kosa, A.-C., Doeraene, E., López Gutiérrez, L., Brion, J. P., & Leroy, K. (2022). PICALM and Alzheimer’s Disease: An Update and Perspectives. Cells, 11(24), 3994. doi:10.3390/cells11243994
  7. 5. De Fisenne, M.-A., Yilmaz, Z., De Decker, R., Suain, V., Buée, L., Ando, K., Brion, J. P., & Leroy, K. (2022). Alzheimer PHF-tau aggregates do not spread tau pathology to the brain via the Retino-tectal projection after intraocular injection in male mouse models. Neurobiology of disease, 174, 105875. doi:10.1016/j.nbd.2022.105875
  8. 6. Ando, K., Erneux, C., Homa, M., Houben, S., De Fisenne, M.-A., Brion, J. P., & Leroy, K. (2021). Dysregulation of Phosphoinositide 5-Phosphatases and Phosphoinositides in Alzheimer's Disease. Frontiers in Neuroscience, 15, 614855. doi:10.3389/fnins.2021.614855
  9. 7. Houben, S., Homa, M., Yilmaz, Z., Leroy, K., Brion, J. P., & Ando, K. (2021). Tau Pathology and Adult Hippocampal Neurogenesis: What Tau Mouse Models Tell us? Frontiers in neurology, 12, 610330. doi:10.3389/fneur.2021.610330
  10. 8. Ando, K., Ndjim, M., Turbant, S., Fontaine, G., Pregoni, G., Dauphinot, L., Yilmaz, Z., Suain, V., Mansour, S., Authelet, M., De Dekker, R., Leroy, K., Delatour, B., Letournel, F., Martin-Négrier, M.-L., Chapon, F., Godfraind, C., Maurage, C.-A., Deramecourt, V., Meyronnet, D., Streichenberger, N., De Paula Rosa Passetti, A. P., Rigau, V., & Burel-Vandenbos, F. (2020). The lipid phosphatase Synaptojanin 1 undergoes a significant alteration in expression and solubility and is associated with brain lesions in Alzheimer’s disease. Acta neuropathologica communications, 8(1). doi:10.1186/s40478-020-00954-1
  11. 9. Houben, S., De Fisenne, M.-A., Ando, K., Vanden Dries, V., Poncelet, L., Yilmaz, Z., Mansour, S., De Decker, R., Brion, J. P., & Leroy, K. (2020). Intravenous injection of PHF-Tau proteins from Alzheimer Brain exacerbates neuroinflammation, Amyloid beta, and tau pathologies in 5XFAD transgenic mice. Frontiers in Molecular Neuroscience, 13, 10.3389/fnmol.2020.00106, 106.
  12. 10. Ando, K., Ferlini, L., Suain, V., Yilmaz, Z., Mansour, S., Le Ber, I., Bouchard, C., Leroy, K., Durr, A., Clot, F., Sarazin, M., Bier, J. C., & Brion, J. P. (2020). de novo MAPT mutation G335A causes severe brain atrophy, 3R and 4R PHF-tau pathology and early onset frontotemporal dementia. Acta neuropathologica communications, 8(1), 94. doi:10.1186/s40478-020-00977-8
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 Suivant >>